PDL BioPharma Inc. Resources | BNET
On MovieTome: See Gyllenhaal as PRINCE OF PERSIA

BNET Industries

PDL BioPharma Inc. (PDLI) is in the Pharma Industry

Revenue
Dec 31 2007
$258.9M
Profit
Dec 31 2007
($21.0M)
Market Cap
Aug 27 2008
$1.4B

Latest News and Analysis

Additional Resources

  • BellwetherReport.com Analyst Opinions on OTEX, PDLI, DISH and ALTR

    BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...

    Articles 2008-08-20

  • PDL BioPharma Announces Investor Conference Call Today

    PDL BioPharma, Inc. PDL (NASDAQ: PDLI)will hold an investor conference call and webcast today at 5:00 p.m.Eastern time following today's announcement of a collaboration agreementwith Bristol-Myers Squibb Company for the co-development andcommercialization of elotuzumab, PDL's phase 1 antibody candidate formultiple myeloma, and an option, exercisable by Bristol-Myers Squibb, toexpand the...

    Articles 2008-08-19

  • Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma

    Elotuzumab Antibody Designed to Target Highly Expressed Cell Surface Protein and Selectively Kill Multiple Myeloma Cells PRINCETON, N.J. & REDWOOD CITY, Calif. -- Bristol-Myers Squibb Company (NYSE: BMY) and PDL BioPharma, Inc. (NASDAQ: PDLI) today announced an agreement for the global development and commercialization of PDL BioPharma's anti-CS1...

    Articles 2008-08-19

  • BellwetherReport.com Analyst Report on YHOO, PDLI, MAXY and GS

    BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews...

    Articles 2008-06-13

  • PDL Announces Changes to Its Board of Directors

    PDL BioPharma, Inc. PDL (NASDAQ: PDLI)today announced changes to its board of directors. L. Patrick Gage, Ph.D. has resigned as a director of PDL due to differencesof opinion among the board members over the prioritization of PDL'sobjectives, and he will no longer serve as interim chief executive officer.In addition, Karen...

    Articles 2008-05-29

  • PDL BioPharma Reports First Quarter 2008 Financial Results

    PDL BioPharma, Inc. PDL (NASDAQ: PDLI)today reported financial results for the quarter ended March 31, 2008. Theresults of the company's commercial and cardiovascular operations segmentare presented as discontinued operations. The assets related to thissegment were sold in March 2008. The financial results for continuing anddiscontinued operations are...

    Articles 2008-05-08

  • Emerging Stock Report for Thursday, May 08, 2008: PUBM Blockbuster Potential!

    TheSUBWAY.com announces the following stocks toits Action List: Public Media Works, Inc. (OTCBB: PUBM), SynchronossTechnologies, Inc. (NASDAQ: SNCR), UTStarcom, Inc. (NASDAQ: UTSI), PDLBioPharma, Inc. (NASDAQ: PDLI). Visit TheSUBWAY's Small Cap Investor Forum Here: http://investor-forum.thesubway.com/ Public Media Works, Inc. (OTCBB: PUBM), a film, music and televisionentertainment and digital media...

    Articles 2008-05-08

  • PDL Biopharma Announces Conversion Rate Adjustment for 2.00% Convertible Senior Notes Due February 15, 2012

    PDL BioPharma, Inc. PDL (NASDAQ: PDLI)today announced an adjustment to the conversion rate for its 2.00%Convertible Senior Notes due February 15, 2012 (the "Notes"), as a resultof its previously announced special cash dividend of $4.25 per share of itscommon stock. The conversion rate, as adjusted, is 61.426 shares of...

    Articles 2008-05-06

  • PDL BioPharma Announces Data Presentations for Antibody Pipeline Products

    PDL BioPharma, Inc. (NASDAQ: PDLI)announced today two presentations of data at medical conferences related tothe company's development-stage antibody products in multiple sclerosis andoncology. Details regarding each of the presentations are summarizedbelow. Copies of the poster and plenary presentations will be available onPDL BioPharma's website at the time of...

    Articles 2008-04-14

  • PDL BioPharma Declares $500 Million Special Cash Dividend and Announces Plan to Separate Its Biotechnology Operations From Its Antibody Humanization Royalty Assets

    PDL BioPharma, Inc. PDL (NASDAQ: PDLI)announced today that its board of directors has: -- declared a special cash dividend of $4.25 per share of common stock, payable to stockholders of record on May 5, 2008, using proceeds from recent asset sales; and-- ...

    Articles 2008-04-10

  • Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility.(Company overview)

    COPENHAGEN, Denmark and REDWOOD CITY, California, March 14 /PRNewswire/ -- - Summary: Genmab's Acquisition of PDL BioPharma's Antibody Manufacturing Facility has Closed. Genmab A/S (OMX: GEN) and PDL BioPharma, Inc. (Nasdaq: PDLI) today announced the closing of the...

    Articles 2008-03-14

  • page 1 of 1

Sort byClose

View by Content TypeClose

View Related Content by Tag Close

  • Incorporated: 1986
  • Employees: 887

PDL BioPharma is a biopharmaceutical company focused on the discovery and development of antibodies in oncology and immunologic diseases. Co. markets its products in the acute-care hospital setting in the U.S. and Canada and generates royalties and other revenues through licensing agreements with several biotechnology and pharmaceutical companies. As of Dec 31 2007, Co. had several investigational antibody-based compounds in clinical development for cancer and immunologic diseases including Daclizumab, Volociximab (M200), HuLuc63, PDL192, NuvionŽ (visilizumab) and Cardene. Co.'s research platform is focused on the discovery of antibodies for the treatment of cancer and immunologic diseases.

Key Competitors

advertisement
PDL BioPharma Inc. Company Info

Board of Directors

Mr. Bradford S. Goodwin

Chairman

Mr. Joseph Klein III

Dr. Richard Murray Ph.D.

Dr. Laurence Jay Korn Ph.D.

Mr. Jon S. Saxe

Mr. Gary A. Lyons

Contact Information

34801 Campus Drive

Fremont, CA

http://www.pdl.com

510 574-1400

NAICS Code

Biological Product (except Diagnostic) Manufacturing: 325414
advertisement